Inactive Instrument

Compugen Ltd. Stock TEL AVIV STOCK EXCHANGE

Equities

IL0010852080

Biotechnology & Medical Research

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 * 37.9M 14B Sales 2025 * 35.29M 13.04B Capitalization 198M 73.09B
Net income 2024 * -13M -4.8B Net income 2025 * -29M -10.71B EV / Sales 2024 * 5.22 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 5.61 x
P/E ratio 2024 *
-17 x
P/E ratio 2025 *
-8.19 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.62%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 57 01-12-31
Director of Finance/CFO 61 22-10-31
Chief Tech/Sci/R&D Officer - 14-12-31
Members of the board TitleAgeSince
Chairman 65 17-10-01
Director/Board Member 68 18-06-10
Director/Board Member 57 18-06-10
More insiders
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW